What diseases are acotinib/concostat mainly used to treat?

Acalabrutinib (Acalabrutinib) is a highly selective BTK (Bruton tyrosine kinase) inhibitor. Its core mechanism of action is to block B cell signaling pathways and reduce the continued proliferation of tumor lymphocytes, thereby exerting anti-tumor effects. As a second-generation BTK-targeted drug, it is designed to inhibit BTK activity more precisely and minimize interference with other enzyme systems. Therefore, it is regarded as an important treatment option in the field of hematological tumors in many countries.

The currently approved indications for acotinib in China are concentrated in three types of malignant tumors B cell origin, the most important of which is chronic lymphocytic leukemia (CLL) . CLL is a lymphoid system tumor that grows slowly but is highly prone to recurrence. Traditional chemotherapy has limited effect on some patients. BTK inhibitors can directly interfere with the signals that tumor cells rely on to grow, and therefore have become one of the treatments recommended by global guidelines. Acotinib is typically used to provide a more sustained, controllable treatment option for patients who have previously received treatment, have progressed, or are intolerant to other regimens.

The second type of indication is small lymphocytic lymphoma (SLL), which is essentially a different manifestation of the same disease as CLL, except that it mainly involves lymph nodes rather than peripheral blood. Acotinib also reduces tumor activity in this type of patients by inhibiting the BTK pathway. It has the characteristics of long-term oral administration and home management, making it easier for patients to maintain their quality of life during treatment.

The third category of indication is mantle cell lymphoma (MCL). MCL is a lymphoma with progressive biological behavior, and patients may still relapse after receiving chemotherapy or immunotherapy. As a precise targeted drug, acotinib can play a role in later-line treatment and provide new treatment directions for patients with multiple recurrences. In international guidelines and overseas clinical practice, MCL is one of its core application groups.

Reference materials:https://www.calquence.com/